Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 10, 2025 10:10 ET | Source: Transparency Market Research

Opioid Use Disorders Market to Reach USD 8.8 Billion by 2034, Driven by Expanding Addiction Treatment Programs | Exclusive Report by Transparency Market Research, Inc.

Wilmington, Delaware, Transparency Market Research Inc. –, Feb. 10, 2025 (GLOBE NEWSWIRE) -- The Opioid Use Disorders Market (오피오이드 사용 장애 시장) is projected to grow from US$ 3.2 billion in 2023 to US$...
January 14, 2025 10:45 ET | Source: Research and Markets

Opioid Use Disorder Market Projected to Reach USD 10.24 Billion by 2030, Growing at a CAGR of 11.15% - Buprenorphine Dominates Market Share, Injectable OUD Medications Gain Traction

Dublin, Jan. 14, 2025 (GLOBE NEWSWIRE) -- The "Opioid Use Disorder Market Size, Share & Trends Analysis Report By Drug, By Route Of Administration, By Distribution Channel, By Region, And...
June 07, 2024 09:18 ET | Source: Research and Markets

Global Substance Use Disorder Markets and Epidemiology Forecast to 2034: SWOT Analysis, Clinical Trials, Marketed & Pipeline Drugs, Unmet Needs

Dublin, June 07, 2024 (GLOBE NEWSWIRE) -- The "Substance Use Disorder Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034" report has been added to ...
June 06, 2024 10:54 ET | Source: Research and Markets

Alcohol-Related Disorders Market and Epidemiology Forecast, 2024-2034, Featuring Analysis of Vivitrol (Alkermes), DCR-AUD (Dicerna Pharmaceuticals) and Other Drugs

Dublin, June 06, 2024 (GLOBE NEWSWIRE) -- The "Alcohol-Related Disorders Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034" report has been added to ...
June 05, 2024 03:49 ET | Source: Research and Markets

Opioid Use Disorder in the 7MM: Epidemiology Insights and Forecast 2024-2034 Featuring Detailed Analysis of Marketed and Late-Stage Pipeline Drugs, Including Subutex and INDV-2000 (Indivior)

Dublin, June 05, 2024 (GLOBE NEWSWIRE) -- The "Opioid Use Disorder Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034" report has been added to ...
January 29, 2024 09:07 ET | Source: Research and Markets

Global Substance Abuse (Alcohol, Cocaine, Marijuana, Nicotine) Treatment Market Report 2024-2030: Emerging Trends and Regional Insights for Products and Treatment Options

Dublin, Jan. 29, 2024 (GLOBE NEWSWIRE) -- The "Global Substance Abuse Treatment Market by Substance Abuse Type (Alcohol Addiction, Cocaine, Marijuana), Product (Behavioral Treatment, Drugs),...
June 09, 2023 07:23 ET | Source: Research and Markets

Global Substance Abuse Treatment Market Review and Forecast to 2030: Alcohol Addiction Commanded the Largest Market Share of 34.27% in 2022, Followed by Nicotine Addiction

Dublin, June 09, 2023 (GLOBE NEWSWIRE) -- The "Global Substance Abuse Treatment Market by Substance Abuse Type (Alcohol Addiction, Cocaine, Marijuana), Product (Behavioral Treatment, Drugs),...
April 17, 2023 07:43 ET | Source: Research and Markets

U.S. Substance Abuse Treatment Market Report 2023: Surging Rate of Drug Addiction and the Growing Prevalence of Alcohol and Smoking Among Teenagers Drives Growth

Dublin, April 17, 2023 (GLOBE NEWSWIRE) -- The "Substance Abuse Treatment Market Research Report by Substance Abuse Type (Alcohol Addiction, Cocaine, Marijuana), Product (Behavioral Treatment,...
November 07, 2022 06:00 ET | Source: InvestmentPitch Media and Love Pharma Inc

InvestmentPitch Media Video Discusses LOVE Pharma’s Plans to Continue Developing a Portfolio of Innovative Products such as Naltrexone Encompassing Transdermal Drug Delivery Applications for Addictions and Long-COVID

VANCOUVER, British Columbia, Nov. 07, 2022 (GLOBE NEWSWIRE) -- LOVE Pharma (CSE:LUV) (FSE:G1Q0) continues with its plans to develop a portfolio of innovative products encompassing transdermal drug...
November 03, 2022 08:45 ET | Source: Love Pharma Inc.

Acquisition Has Love Pharma’s Naltrexone on NIH Shortlist to Address Unmet Medical Need—Treatment for Long Covid

NEW YORK, NY, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Love Pharma Inc. (CSE: LUV) (FSE: G1Q0), an international mental health and sexual wellness company, has been explicit about its plans to develop a...

Next Page keyboard_arrow_right